Neoadjuvant chemoradiotherapy and chemotherapy in patients with locally advanced rectal cancer

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter A. Soliman
Citation Annals of Oncology (2016) 27 (2): 86-101. 10.1093/annonc/mdw201
Authors A. Soliman1, N. Attia2, M. Khalaf3, A. Attia4, H. Fakhry5
  • 1Assiut University, Assiut, Egypt, /
  • 2South Cancer Institute, Assiut, Egypt, /
  • 3Assiut University Hospital, Assiut, Egypt, /
  • 4South National Cancer Institute, Assiut, Egypt, /
  • 5South Egypt Cancer Institute, Assiut University, Assiut, Egypt, /

Abstract

Evaluate the role of neoadjuvant chemoradiotherapy (CRT) followed by an additional cycle of chemotherapy and total mesorectal excision (TME) in patients with locally advanced rectal cancer on the rate of pathologic complete response (pCR) and tumor downstaging, their impact on survival and evaluation of treatment related toxicity and surgical complications.